Clinical trial · Interventional
A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma
NCT01802138CI-TRIAL-00038012completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Activated T cell were manufactured through in vitro T cell expansion of autologous T cell. We designed this study to determine the feasibility and safety of Activated T-lymphocyte cell therapy for refractory/relapsed neuroblastoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Activated T lymphocyte | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Activated T-lymphocyte
- description
- This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma. If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated.
- interventionNames
- Biological: Activated T lymphocyte
Primary outcomes (1)
- measure
- T cell count after in vitro expansion
- timeFrame
- up to 13 weeks
- description
- T cell count after in vitro expansion Evaluation of safety
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Informed consent * Age 21 years or younger * Histologically confirmed neuroblastoma * Progressive disease after standard treatment or relapsed patient * ECOG scale (ECOG-PS) ≤2 * Expected survival at least 3 months Exclusion Criteria: * Patients with autoimmune disease * Patients with immunodeficiency * Other malignancy 5 year prior to this study * Severe organ dysfunction * Severe allergic disease * Severe psychiatric disorder * Pregnancy or lactating woman
References
Publications (0)
Data not yet available
No reference posted for this study.